secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2022-12-27T23:59:59+00:00
Accession:  0001104659-22-130170
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts IND for KPI-012; Kala raises $25M, applies to transfer to Nasdaq Capital Market
--------------------------------------------------------------------------------

- FDA accepted IND for lead candidate KPI-012 for PCED; Phase 2b trial to start Q1 2023, topline data expected Q1 2024.
- Second closing of private placement yielded $25M gross proceeds from sale of 43,478 preferred shares at $575 each.
- Company expects existing cash, including private placement proceeds, to fund operations for ~24 months.
- Entered loan amendment with Oxford Finance requiring $5M prepayments by June 2023 and Jan 2024, and allows Nasdaq transfer.
- Applied to transfer listing from Nasdaq Global Select to Capital Market due to non-compliance with minimum market value requirements; believes it now meets Capital Market standards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000110465922130170/0001104659-22-130170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000110465922130170/tm2233519d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-130170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer